molecules of the month


potent, selective, Q2W IV CD73 inhibitor

completed Ph. I in HV, in dev. for cancer imm.

from opt. of known nucleotide CD73 inh.

J. Med. Chem., Jul. 20, 2020

Arcus Biosciences, Hayward, CA

Structure of AB680, a potent small-molecule inhibitor of CD73
1 min read

AB680 is a potent (5 pM) and selective inhibitor of CD73, a nucleotidase that metabolizes AMP to immunosuppressive extracellular adenosine. AB680 is intended to be used in combination with checkpoint inhibitor biologics in cancer immunotherapy, and has a PK profile for biweekly (Q2W) IV dosing in humans based on a Ph. I study in healthy volunteers.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: